SCHEMBL2801230

SCHEMBL2801230

Cc1ccc(C)c(Nc2c(C(=O)N3CCC(C4CCCCC4)CC3)cnc3c(C(=O)O)cnn23)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.41
DHODH Q02127 3/20 0.40
TRPC3 Q13507 1/20 0.40
TRPC6 Q9Y210 1/20 0.40
PDE4B Q07343 1/20 0.39
KDM4E B2RXH2 4/20 0.38
HPGD P15428 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDR P35968 1/20 0.37
GAA P10253 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
THRB P10828 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2798971 0.90 KDM4E (0.43) TRPC3TRPC6PDE4BKDM4EHPGD
SCHEMBL2803840 0.88 HPGD (0.36) TP53TRPC3TRPC6KDM4EHPGD
SCHEMBL2799436 0.87 TP53 (0.44) TP53PDE4BNPC1RAB9AALDH1A1
SCHEMBL2799665 0.84 FASN (0.42) TP53NPC1RAB9AALDH1A1THRB
SCHEMBL2800055 0.83 SPR (0.44) TP53KDM4EHPGDALDH1A1HSD17B10
SCHEMBL2801551 0.83 FASN (0.39) TP53DHODHKDM4EHPGDALDH1A1
SCHEMBL2800858 0.81 TP53 (0.42) TP53PDE4BKDM4EHPGDRAB9A
SCHEMBL2800107 0.80 SPR (0.39) TP53KDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL2800432 0.79 KDM4E (0.41) TP53PDE4BKDM4EHPGDNPC1
SCHEMBL2800415 0.78 SIRT5 (0.43) TP53NPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 TP53 241/4885DHODH 446/4885TRPC3 3732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.